• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cronos Group Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/22/26 5:04:19 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CRON alert in real time by email
    cron-20260618
    falseCRONOS GROUP INC.0001656472StaynerCanada001-38403Ontario00016564722026-06-182026-06-18

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 18, 2026

    CRONOS GROUP INC.
    (Exact name of registrant as specified in its charter)
    British Columbia, Canada
    001-38403
    N/A
    (State or other jurisdiction(Commission(I.R.S. Employer
    of incorporation)File Number)Identification No.)
    4491 Concession Rd 12
    Stayner, Ontario
    L0M 1S0
    (Address of principal executive offices)(Zip Code)

    Registrant’s telephone number, including area code: (416) 504-0004

    Not Applicable
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Shares, no par valueCRONThe NASDAQ Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 5.07.    Submission of Matters to a Vote of Security Holders.
    Cronos Group Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders on June 18, 2026 (the “Meeting”). The proposals voted upon at the Meeting and the final results of the shareholder vote on each proposal are set forth below. Each of the proposals is summarized in greater detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026 (the “Proxy Statement”).
    Proposal No. 1: Election of Directors
    Name of NomineeForWithheldBroker Non-Votes
    Jason Adler220,505,353 1,291,292 50,032,114 
    Darren Broughton220,506,387 1,290,258 50,032,114 
    Murray Garnick219,627,749 2,168,896 50,032,114 
    Michael Gorenstein207,751,369 14,045,276 50,032,114 
    Dominik Meier220,426,444 1,370,201 50,032,114 
    James Rudyk216,463,958 5,332,687 50,032,114 
    Elizabeth Seegar220,476,757 1,319,888 50,032,114 
    Proposal No. 2: Adoption of an advisory (non-binding) resolution to approve the compensation of the Company’s named executive officers
    ForAgainstAbstainedBroker Non-Votes
    219,776,593 1,624,630 395,422 50,032,114 
    Proposal No. 3: Adoption of an advisory (non-binding) resolution on the frequency of future “say on pay” votes as described in the Proxy Statement
    One YearTwo YearsThree YearsAbstain
    207,874,325 108,955 3,074,365 10,739,000 
    Proposal No. 4: Appointment of Davidson & Company LLP, the Company’s independent registered public accounting firm, to serve as the Company’s independent auditor for fiscal year 2026 and to authorize the Board of Directors of the Company to fix the independent auditors’ remuneration
    ForWithheld
    268,504,336 3,324,423 





    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    CRONOS GROUP INC.
    Dated: June 22, 2026By:/s/ Michael Gorenstein
    Name: Michael Gorenstein
    Title: President and Chief Executive Officer


    Get the next $CRON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRON

    DatePrice TargetRatingAnalyst
    1/27/2026Buy
    Canaccord Genuity
    11/2/2022$3.00Mkt Perform
    Bernstein
    7/28/2022Hold → Buy
    Canaccord Genuity
    5/11/2022Neutral → Sector Outperform
    CIBC
    3/22/2022Underweight → Equal Weight
    Barclays
    3/7/2022$4.00 → $3.00Neutral
    Piper Sandler
    2/22/2022$7.00 → $4.25Sell
    Canaccord Genuity
    2/22/2022$7.00 → $4.00Neutral
    Piper Sandler
    More analyst ratings

    $CRON
    SEC Filings

    View All

    Cronos Group Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Cronos Group Inc. (0001656472) (Filer)

    6/22/26 5:04:19 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Cronos Group Inc.

    10-Q - Cronos Group Inc. (0001656472) (Filer)

    5/11/26 7:33:01 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Cronos Group Inc. (0001656472) (Filer)

    5/11/26 7:32:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cronos Group Inc. Announces Results of 2026 Annual Meeting of Shareholders

    TORONTO, June 22, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Thursday, June 18, 2026 (the "Meeting"), shareholders holding a total of 271,828,759 common shares of the Company voted in person or by proxy, representing 72.24% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company’s definitive proxy statement dated April 24, 2026, was elected as a director of the Company, with each director receiving in excess of 93.6% of the votes cast in favor of his or her election. The detailed results of the vote for th

    6/22/26 5:30:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Announces Extension of Share Repurchase Program to the Toronto Stock Exchange

    TORONTO, June 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. ("Cronos" or the "Company") (NASDAQ:CRON) (TSX:CRON), an innovative global cannabis company,  announced today that it has filed with the Toronto Stock Exchange (the "TSX"), and the TSX has accepted, the Company's notice of intention to make a normal course issuer bid (the "TSX NCIB"). As previously announced by Cronos, the Company's Board approved a share repurchase program on May 8, 2026, which commenced on May 14, 2026 and is expected to terminate on May 13, 2027, unless earlier terminated (the "Share Repurchase Program"). Pursuant to the TSX NCIB, repurchases under the Share Repurchase Program may now also be made from time t

    6/16/26 4:15:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Spinach® is the Number One Vape Brand in Canada

    TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos"), an innovative global cannabinoid company, today announced that its Spinach® vape portfolio has become the top‑selling vape brand in Canada, capturing 10.4%1 market share of the total vapes category in April 2026, a position that Cronos has held since January 2026. Since entering the vape category, the Spinach® brand has built a best‑in‑class offering rooted in quality, flavor, and technology. Spinach® vapes are crafted using high‑purity extracts, feature vibrant and distinctive terpene profiles, and utilize advanced hardware designed to deliver smooth, reliable performance for adult consumers

    6/11/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Doucet Terrence Gregory Joseph converted options into 10,597 shares and covered exercise/tax liability with 5,199 shares, increasing direct ownership by 5% to 110,588 units (SEC Form 4)

    4 - Cronos Group Inc. (0001656472) (Issuer)

    5/14/26 4:58:49 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Wagner Adam converted options into 10,367 shares, increasing direct ownership by 11% to 103,987 units (SEC Form 4)

    4 - Cronos Group Inc. (0001656472) (Issuer)

    5/14/26 4:58:02 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Buggy Shannon converted options into 20,622 shares and covered exercise/tax liability with 9,179 shares, increasing direct ownership by 7% to 178,322 units (SEC Form 4)

    4 - Cronos Group Inc. (0001656472) (Issuer)

    5/14/26 4:57:28 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Cronos Group

    Canaccord Genuity initiated coverage of Cronos Group with a rating of Buy

    1/27/26 9:29:20 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Cronos Group with a new price target

    Bernstein initiated coverage of Cronos Group with a rating of Mkt Perform and set a new price target of $3.00

    11/2/22 6:32:18 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Cronos Group from Hold to Buy

    7/28/22 9:01:16 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Leadership Updates

    Live Leadership Updates

    View All

    Cronos Group Inc. Announces Results of 2026 Annual Meeting of Shareholders

    TORONTO, June 22, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Thursday, June 18, 2026 (the "Meeting"), shareholders holding a total of 271,828,759 common shares of the Company voted in person or by proxy, representing 72.24% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company’s definitive proxy statement dated April 24, 2026, was elected as a director of the Company, with each director receiving in excess of 93.6% of the votes cast in favor of his or her election. The detailed results of the vote for th

    6/22/26 5:30:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. Announces Results of 2025 Annual Meeting of Shareholders

    TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Friday, June 20, 2025 (the "Meeting"), shareholders holding a total of 276,989,452 common shares of the Company voted in person or by proxy, representing 71.87% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's definitive proxy statement dated April 25, 2025 was elected as a director of the Company, with each director receiving in excess of 92.3% of the votes cast in favor of his or her election. The detailed results of the vote for the e

    6/23/25 5:30:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Appoints Anna Shlimak as Chief Financial Officer

    TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced the appointment of Anna Shlimak as Chief Financial Officer, effective today. Ms. Shlimak, who previously served as Cronos' Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos' leadership team for the last seven years, playing a key role in shaping the Company's strategy, operational efficiencies, and engagement with the financial and

    3/19/25 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

    SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

    4/25/24 6:39:55 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

    SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

    12/19/22 8:47:03 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Financials

    Live finance-specific insights

    View All

    Cronos Group Inc. to Hold 2026 First Quarter Earnings Conference Call on May 11, 2026

    TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2026 first quarter earnings conference call on Monday, May 11, 2026 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on th

    4/20/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2025 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2026

    TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 fourth quarter and full-year earnings conference call on Thursday, February 26, 2026 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be arch

    2/12/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2025 Third Quarter Earnings Conference Call on November 6, 2025

    TORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 third quarter earnings conference call on Thursday, November 6, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay

    10/23/25 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care